Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]

Cross-linking agents are frequently used to restore corneal properties after decellularization, and it is especially important to select an appropriate method to avoid excessive cross-linking. In addition, how to promote wound healing and how to improve scar formation require further investigation....

Full description

Saved in:
Bibliographic Details
Main Authors: Yansha Hao, Jingting Zhou, Ju Tan, Feng Xiang, Zhongliang Qin, Jun Yao, Gang Li, Mingcan Yang, Lingqin Zeng, Wen Zeng, Chuhong Zhu
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2025-11-01
Series:Bioactive Materials
Online Access:http://www.sciencedirect.com/science/article/pii/S2452199X25003044
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849248081417076736
author Yansha Hao
Jingting Zhou
Ju Tan
Feng Xiang
Zhongliang Qin
Jun Yao
Gang Li
Mingcan Yang
Lingqin Zeng
Wen Zeng
Chuhong Zhu
author_facet Yansha Hao
Jingting Zhou
Ju Tan
Feng Xiang
Zhongliang Qin
Jun Yao
Gang Li
Mingcan Yang
Lingqin Zeng
Wen Zeng
Chuhong Zhu
author_sort Yansha Hao
collection DOAJ
description Cross-linking agents are frequently used to restore corneal properties after decellularization, and it is especially important to select an appropriate method to avoid excessive cross-linking. In addition, how to promote wound healing and how to improve scar formation require further investigation. To ensure the safety and efficacy of animal-derived products, we designed bioartificial corneas (BACs) according to the criteria for Class III medical devices. Our BACs do not require cross-linking agents and increase mechanical strength via self-cross-linking of aldehyde-modified hyaluronic acid (AHA) and carboxymethyl chitosan (CMC) on the surface of decellularized porcine corneas (DPCs). The results showed that the BACs had good biocompatibility and transparency, and the modification enhanced their antibacterial and anti-inflammatory properties in vitro. Preclinical animal studies showed that the BACs can rapidly regenerate the epithelium and restore vision within a month. After 3 months, the BACs were gradually filled with epithelial, stromal, and neuronal cells, and after 6 months, their transparency and histology were almost normal. In addition, side effects such as corneal neovascularization, conjunctival hyperemia, and ciliary body hyperemia rarely occur in vivo. Therefore, these BACs show promise for clinical application for the treatment of infectious corneal ulcers and as a temporary covering for corneal perforations to achieve the more time.
format Article
id doaj-art-ce0309bf36f64422bcfee4bce5ae8ba5
institution Kabale University
issn 2452-199X
language English
publishDate 2025-11-01
publisher KeAi Communications Co., Ltd.
record_format Article
series Bioactive Materials
spelling doaj-art-ce0309bf36f64422bcfee4bce5ae8ba52025-08-20T03:58:00ZengKeAi Communications Co., Ltd.Bioactive Materials2452-199X2025-11-015370470510.1016/j.bioactmat.2025.07.011Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]Yansha Hao0Jingting Zhou1Ju Tan2Feng Xiang3Zhongliang Qin4Jun Yao5Gang Li6Mingcan Yang7Lingqin Zeng8Wen Zeng9Chuhong Zhu10Department of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China; Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing, 400038, China; State Key Laboratory of Trauma, Burnand Combined Injury, Chongqing, ChinaDepartment of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China; Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing, 400038, China; State Key Laboratory of Trauma, Burnand Combined Injury, Chongqing, ChinaDepartment of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China; Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing, 400038, China; State Key Laboratory of Trauma, Burnand Combined Injury, Chongqing, ChinaDepartment of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China; Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing, 400038, China; State Key Laboratory of Trauma, Burnand Combined Injury, Chongqing, ChinaDepartment of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China; Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing, 400038, China; State Key Laboratory of Trauma, Burnand Combined Injury, Chongqing, China; Zhong Zhi Yi Gu Research Institute, Chongqing Jiukang Medical Research Institute Co., Ltd., ChinaHong Chang Biotechnology Co., Ltd, Guangzhou, 510700, ChinaDepartment of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China; Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing, 400038, China; State Key Laboratory of Trauma, Burnand Combined Injury, Chongqing, ChinaDepartment of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China; Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing, 400038, China; State Key Laboratory of Trauma, Burnand Combined Injury, Chongqing, ChinaDepartment of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China; Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing, 400038, China; State Key Laboratory of Trauma, Burnand Combined Injury, Chongqing, ChinaDepartment of Cell Biology, Third Military Army Medical University, Chongqing, 400038, China; Corresponding author. Department of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China.Department of Anatomy, Engineering Research Center for Organ Intelligent Biological Manufacturing of Chongqing, Key Lab for Biomechanics and Tissue Engineering of Chongqing, Third Military Medical University, Chongqing, 400038, China; Engineering Research Center of Tissue and Organ Regeneration and Manufacturing, Ministry of Education, Chongqing, 400038, China; State Key Laboratory of Trauma, Burnand Combined Injury, Chongqing, China; Corresponding author. Department of Cell Biology, Third Military Army Medical University, Chongqing, 400038, China.Cross-linking agents are frequently used to restore corneal properties after decellularization, and it is especially important to select an appropriate method to avoid excessive cross-linking. In addition, how to promote wound healing and how to improve scar formation require further investigation. To ensure the safety and efficacy of animal-derived products, we designed bioartificial corneas (BACs) according to the criteria for Class III medical devices. Our BACs do not require cross-linking agents and increase mechanical strength via self-cross-linking of aldehyde-modified hyaluronic acid (AHA) and carboxymethyl chitosan (CMC) on the surface of decellularized porcine corneas (DPCs). The results showed that the BACs had good biocompatibility and transparency, and the modification enhanced their antibacterial and anti-inflammatory properties in vitro. Preclinical animal studies showed that the BACs can rapidly regenerate the epithelium and restore vision within a month. After 3 months, the BACs were gradually filled with epithelial, stromal, and neuronal cells, and after 6 months, their transparency and histology were almost normal. In addition, side effects such as corneal neovascularization, conjunctival hyperemia, and ciliary body hyperemia rarely occur in vivo. Therefore, these BACs show promise for clinical application for the treatment of infectious corneal ulcers and as a temporary covering for corneal perforations to achieve the more time.http://www.sciencedirect.com/science/article/pii/S2452199X25003044
spellingShingle Yansha Hao
Jingting Zhou
Ju Tan
Feng Xiang
Zhongliang Qin
Jun Yao
Gang Li
Mingcan Yang
Lingqin Zeng
Wen Zeng
Chuhong Zhu
Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]
Bioactive Materials
title Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]
title_full Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]
title_fullStr Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]
title_full_unstemmed Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]
title_short Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]
title_sort corrigendum to preclinical evaluation of the safety and effectiveness of a new bioartificial cornea bioact mater 2023 8 29 265 278
url http://www.sciencedirect.com/science/article/pii/S2452199X25003044
work_keys_str_mv AT yanshahao corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT jingtingzhou corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT jutan corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT fengxiang corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT zhongliangqin corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT junyao corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT gangli corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT mingcanyang corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT lingqinzeng corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT wenzeng corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278
AT chuhongzhu corrigendumtopreclinicalevaluationofthesafetyandeffectivenessofanewbioartificialcorneabioactmater2023829265278